Clinical Trial Update: A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial updates on GC1118 combined with chemotherapy are completed in Phase 1/2 for metastatic colorectal cancer and solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Solid Tumor

Drugs mentioned

• GC1118 (recombinant human anti-EGFR antibody)

Snippet

Sponsor: Green Cross Corporation | Conditions: Metastatic Colorectal Cancer, Solid Tumor | Phase 1, Phase 2 | Status: COMPLETED